Welcome to our dedicated page for Hims & Hers Health news (Ticker: HIMS), a resource for investors and traders seeking the latest updates and insights on Hims & Hers Health stock.
Hims & Hers Health Inc (HIMS) delivers innovative telehealth solutions through its direct-to-consumer platform, connecting users with licensed professionals for personalized care, wellness products, and prescription services. This news hub provides investors and industry observers with essential updates about the company’s operational milestones and market developments.
Access real-time announcements including quarterly earnings reports, strategic partnerships, product expansions, and regulatory filings. Our curated collection ensures you stay informed about HIMS’ position in the competitive digital healthcare sector without needing to track multiple sources.
Key updates across these areas:
Financial Performance: Earnings calls and SEC filings
Service Innovations: New telehealth offerings and treatment categories
Strategic Growth: Partnerships and market expansion initiatives
Regulatory Compliance: FDA updates and healthcare policy impacts
Bookmark this page for streamlined access to verified HIMS developments. Combine these updates with our analysis tools on Stock Titan to monitor the company’s evolving role in reshaping accessible healthcare solutions.
Define Ventures, a major venture capital firm focusing on early-stage health tech companies, has appointed Bruce Broussard as venture partner. Broussard, former CEO and president of Humana, brings extensive experience in scaling companies and fostering innovation across various healthcare sectors. His role will involve guiding founders, shaping investment strategies, and strengthening partnerships with large healthcare organizations.
Broussard's decision to join Define Ventures is rooted in his belief in the firm's unique position to transform healthcare. His appointment follows that of Frank Williams, co-founder and former CEO of Evolent, who joined as venture partner earlier this year. Define Ventures, with $800 million in assets under management, partners with companies at seed, series A, and series B stages, including notable firms like Hims & Hers and Unite Us.
Hims & Hers Health, Inc. (NYSE: HIMS) has appointed Dr. Jessica Shepherd as the first Chief Medical Officer of Hers. With nearly 20 years of clinical experience in obstetrics, gynecology, and surgery, Dr. Shepherd will guide the clinical expertise for the Hers brand across sexual health, dermatology, weight loss, and mental health.
The appointment aims to address the women's health gap, as women spend 25% more of their lives in poor health than men. Hims & Hers seeks to provide accessible and affordable personalized care for women, with plans to expand into treatments for specific conditions like menopause and post-partum care.
Dr. Shepherd joins a team of medical leaders at Hims & Hers with over 100 years of combined experience across various health fields, forming the clinical backbone of the company.
Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, has announced it will release its third quarter 2024 financial results on Monday, November 4, 2024, after the market closes. The company will host a live conference call at 5:00 p.m. ET on the same day to discuss the results.
Interested parties can access the conference call by dialing (888) 510-2630 for U.S. participants or (646) 960-0137 for international participants, using the conference ID 1704296. Additionally, a live audio webcast will be available on the company's investor relations website at https://investors.hims.com, where it will remain archived for one year.
Hims & Hers Health (NYSE:HIMS) is set to join the S&P SmallCap 600 index, replacing Vector Group (NYSE:VGR), effective prior to the opening of trading on Wednesday, October 9, 2024. This change is due to JT Group's pending acquisition of Vector Group. The addition of Hims & Hers Health to the index represents a shift in the Health Care sector, while Vector Group's deletion removes a Consumer Staples component.
The S&P SmallCap 600 is part of the S&P Dow Jones Indices, which is the largest global resource for essential index-based concepts, data, and research. S&P Dow Jones Indices, a division of S&P Global (NYSE: SPGI), is known for iconic financial market indicators such as the S&P 500® and the Dow Jones Industrial Average®.
Hims & Hers Health (NYSE: HIMS) has announced a Service Appreciation Initiative offering access to compounded GLP-1 injections for weight loss at $99/month to eligible U.S. military, veterans, teachers, nurses, and first responders. This represents up to a 50% discount on these treatments. The initiative aims to increase access to safe and affordable weight loss solutions for these groups.
Based on self-reported data from approximately 12,000 customers, Hims & Hers reports that customers lost an average of 10.2 pounds on compounded GLP-1 injections and 6.3 pounds on non-GLP-1 compounded oral medication kits after about 4 weeks. The company emphasizes a holistic approach to weight management, including personalized treatment plans by licensed healthcare providers.
Hims & Hers Health (NYSE: HIMS) reported strong Q2 2024 financial results, with revenue reaching $315.6 million, up 52% year-over-year. The company achieved net income of $13.3 million and Adjusted EBITDA of $39.3 million. Subscribers grew to 1.9 million, a 43% increase year-over-year. Hims & Hers raised its full-year 2024 guidance, projecting revenue between $1.37 billion to $1.40 billion and Adjusted EBITDA between $140 million to $155 million. The company's growth strategy, focusing on affordable and personalized health solutions, continues to resonate with consumers, driving both revenue growth and profitability.
Hims & Hers Health, Inc. (NYSE: HIMS) has appointed Kåre Schultz to its Board of Directors. Schultz brings extensive experience from his leadership roles at Novo Nordisk, Teva Pharmaceutical Industries, and Lundbeck. His expertise in the healthcare and pharmaceutical industries is expected to help Hims & Hers increase access to health and wellness solutions.
CEO Andrew Dudum highlighted Schultz's valuable perspective as the company aims to combine clinical excellence, healthcare, and technology. Schultz expressed enthusiasm for Hims & Hers' potential to transform healthcare by leveraging modern tools to improve access to health solutions. He joins a diverse board that includes leaders from various industries, such as former Cleveland Clinic CEO Dr. Toby Cosgrove and former Netflix CFO David Wells.
Hims & Hers Health (NYSE: HIMS), a leading health and wellness platform, has announced its schedule for reporting second quarter 2024 financial results. The company will release its results on August 5, 2024, after market close, followed by a live conference call at 5:00 p.m. ET. Investors can access the call via phone or audio webcast.
Additionally, Hims & Hers management will participate in two upcoming investor conferences:
- Canaccord Genuity's 44th Annual Growth Conference on August 14, 2024 in Boston
- Seaport Research Partner's Annual Summer Virtual Investor Conference on August 21, 2024
The Canaccord Genuity conference will be webcast live and archived on the company's investor relations website.
Hims & Hers has introduced GLP-1 injections to its weight loss program, offering an affordable and personalized solution starting at $199 per month. This addition complements their existing oral medication kits, addressing the shortage and high costs of branded medications like Ozempic® and Wegovy®. The company has secured a partnership with a leading US manufacturer to provide these injections, helping millions manage obesity effectively. The holistic program includes medical consultations, diet, and exercise advice. Hims & Hers aims to exceed $100M in revenue by the end of 2025 with this expanded offering.
Hims & Hers Health (NYSE: HIMS) has appointed Anja Manuel to its Board of Directors. Manuel brings vast experience in government relations, foreign policy, and regulatory issues, having co-founded the consulting firm Rice, Hadley, Gates & Manuel She is expected to help Hims & Hers innovate and expand personalized healthcare access. Manuel's background includes serving on boards of Ripple Labs and Overseas Shipping Group, and roles at the U.S. State Department, WilmerHale, and Salomon Brothers. She holds degrees from Stanford and Harvard Law School.
FAQ
What is the current stock price of Hims & Hers Health (HIMS)?
What is the market cap of Hims & Hers Health (HIMS)?
